This Article Full Text Full Text (PDF) All Versions of this Article: 30/3/280    most recent Author Manuscript (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pectasides, D. Articles by Economopoulos, T. Search for Related Content PubMed PubMed Citation Articles by Pectasides, D. Articles by Economopoulos, T.

Testicular Function in Poor-Risk Nonseminomatous Germ Cell Tumors Treated With Methotrexate, Paclitaxel, Ifosfamide, and Cisplatin Combination Chemotherapy

A. MACHERAS

From the ^* Second Department of Internal Medicine, Propaedeutic, Oncology Section; and the Third Department of Surgery, University of Athens, Attikon University Hospital, Haidari, Athens, Greece

Correspondence to: Dr D. Pectasides, Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece (e-mail: pectasid{at}otenet.gr).

Our objective was to investigate the impact of methotrexate, paclitaxel, ifosfamide, and cisplatin (M-TIP) on long-term fertility in poor-risk nonseminomatous germ cell tumors (NSGCT). Thirty patients with poor-risk NSGCT (median age, 29 years; range, 17–62 years) were treated with methotrexate 250 mg/m² with folinic acid rescue (day 1) and paclitaxel 175 mg/m² (day 1), followed by ifosfamide 1.2 g/m² and cisplatin 20 mg/m² (days 2–6). Treatment consisted of 4 cycles of M-TIP administered every 3 weeks. Twenty-one patients were continuously disease-free at a median follow-up of 5.3 years (range, 0.9–8.4 years). Sperm count and hormonal analyses were examined prechemotherapy (30 patients) and postchemotherapy (21 patients). Counts were classified as follows: lower than 1 x 10⁶/mL, azoospermia; 1–20 x 10⁶/mL, oligospermia (OS); higher than 20 x 10⁶/mL, normospermia (NS). Patients were followed for a median of 2.3 years (range, 0.9–3.8 years) postchemotherapy. The prechemotherapy median luteinizing hormone (LH) serum levels were slightly above the upper normal limit, whereas the serum levels of follicle-stimulating hormone (FSH) and testosterone (T) were within the reference interval. Eleven (52.3%) patients had NS prechemotherapy. Among the patients with NS, 72.7% still had NS following chemotherapy. Overall, 17 of 21 (80.9%; 33.3% OS and 47.6% NS) patients had recovery of spermatogenesis after treatment. The median FSH serum levels were significantly elevated at least 1 year postchemotherapy when compared with the pretreatment levels. Eighteen months after the completion of chemotherapy the median FSH levels had returned to the reference limits. Serum LH and T levels were unaffected by chemotherapy. Prior to chemotherapy 4 of 30 patients had fathered 5 children. Since completion of chemotherapy, 5 patients have fathered 5 children. The majority of men with poor-risk germ cell tumors who were treated with the M-TIP regimen demonstrated recovery spermatogenesis after treatment, and Leydig cell function was unaffected.

     Key words: Fertility, gonadal toxicity

This article has been cited by other articles:

				R. Tripathi, T. Samadder, S. Gupta, A. Surolia, and C. Shaha Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors Mol. Cancer Ther., February 1, 2011; 10(2): 255 - 268. [Abstract] [Full Text] [PDF]